1Atkinson MA, Eisenbarth GS. Type 1 diabetes., new perspectives on disease pathogenesis and treatment[J]. Lancet, 2001, 358(9277): 221-229.
2Barker JM, Barriga KJ, Yu L, et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoirnmunity Study in the Young (DAISY)[J]. J Clin Endocrinol Metab, 2004, 89(8) : 3896-3902.
3Imura H, Nakao K, Shimatsu A, et al. Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus[J]. N Engl J Med, 1993, 329(10) .. 683-689.
4Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress hy acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes[J]. JAMA, 2006, 295(14): 1681-1687.
5ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes [J]. N Engl J Med, 2008, 358(24) : 2560-2572.
6Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes [J]. N Engl J Med, 2008, 358(24):2545-2559.
7Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes[J]. N Engl J Med, 2009, 360 (2) : 129-139.
8Holman RR, Paul SK, Bethel MA, etal. 10-year follow-up of intensive glucose control in type 2 diabetes[J]~. N Engl J Med, 2008, 359(15):1577-1589.
9Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes[J]. N Engl J Med, 2005, 353(25): 2643-2653.
10Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifaetorial intervention on mortality in type 2 diabetes[J]. N Engl J Med, 2008, 358 (6) : 580-591.
